Language Shapes Capital, and “Biopharma” Quietly Distorts Everything
Life sciences believe we are governed by data, rigor, probability curves, and Kaplan Meier plots.
Biotech Innovation Is Not Just Science. It Is Execution.
Over the last several weeks, I have had a series of conversations with emerging biotech leaders that all landed in roughly the same place. Different companies. Different modalities. Different stages. Same underlying challenge.
Biotech Is Different. And If We Want Breakthrough Medicines, We Cannot Wait for Perfect Conditions.
Biotechnology is not a pipeline category or a procurement line. It is the upstream engine of scientific progress. It is an ecosystem built on platforms, talent, and the courage to pursue ideas that will not survive a traditional risk filter. Biotech is different. But the system around it is…
Biotech vs. Biopharma: Why the Distinction Now Matters Again
I strongly believe that biotech and pharma are different and nowhere is that clearer than in how the United States is responding to China in biotechnology. Biotech is increasingly being treated as strategic infrastructure, spanning manufacturing, data, platforms, and know-how. Pharma, meanwhile,…
Biotechnology Was Born Different. We Should Stop Pretending Otherwise!
Biotechnology was never meant to be a subset of traditional pharmaceuticals. That distinction mattered at the beginning, and it still matters today for United States competitiveness and, more importantly, for patients.